Evidence map›Paper›PMID 40371307›Full record

ArticleSAGE open medical case reports2025

Rituximab treatment in non-lupus full-house nephropathy: A case report.

Caroline Gee, Dao Le, Matthew D Nguyen, Anthony Sisk, Ramy Hanna

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in SAGE open medical case reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Caroline GeeDivision of Nephrology, Hypertension and Kidney Transplantation, University of California, Irvine, CA, USA.ORCID https://orcid.org/0009-0002-3704-9353
Dao LeDivision of Nephrology, Hypertension and Kidney Transplantation, University of California, Irvine, CA, USA.
Matthew D NguyenDivision of Nephrology, Hypertension and Kidney Transplantation, University of California, Irvine, CA, USA.ORCID https://orcid.org/0000-0002-6517-041X
Anthony SiskDivision of Pathology and Laboratory Medicine, University of California, Los Angeles, CA, USA.
Ramy HannaDivision of Nephrology, Hypertension and Kidney Transplantation, University of California, Irvine, CA, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Non-lupus full-house nephropathy describes a pattern of "full-house" immunofluorescence on renal biopsy in the absence of clinical or serologic markers for systemic lupus erythematosus. It is a rare disease with a broad range of etiologies, including idiopathic, secondary, or a prodrome of systemic lupus erythematosus. Current treatment options are lacking, with mixed results in the literature for varied immunosuppressive regimens. Rituximab, a selective anti-CD20 B-cell monoclonal antibody, has shown success in immune-complex mediated glomerular diseases but has not been commonly used or studied in non-lupus full-house nephropathy. Here, we present a case of non-lupus full-house nephropathy that was refractory to first-line immunosuppressants, in which two rounds of rituximab treatment achieved a positive response. This case emphasizes the need for systemic analysis of rituximab use in non-lupus full-house nephropathy, particularly given its mixed etiologies and presentations.

Indexed as

immunofluorescencenon-lupus full house nephropathyrituximabsystemic lupus erythematosus

Identifiers

PMID40371307
PMCPMC12075972

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.